🟢 97/100

This product looks safe

  • Niacin: 100mg is 2.9× the Tolerable Upper Intake Level (35mg)
  • 27% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 100mg is 2.9× the Tolerable Upper Intake Level (35mg)

Label Data

8 Capsule(s) Serving Size
30 Servings
Other Combinations Product Type
27% Evidence Coverage

Supplement Facts — Evidence Check

100 mg (500% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 2.9× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 100mg UL 35mg
20 mg (1000% DV)
📊 15.4× RDA — above typical dose (UL: 100 mg) 📚 113 studies (Tier A: 3, B: 35)
RDA 1.3mg This product: 20mg UL 100mg
60 mcg (1000% DV)
📊 25.0× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 0.06mg
1116 mg
📊 Market median: 17.4mg (161 products)
Median 17.4mg This product: 1116mg
932 mg
📊 Market median: 500.0mg (159 products)
Median 500.0mg This product: 932mg
Phenylalanine
924 mg
Threonine
884 mg
Valine
692 mg
Histidine
656 mg
608 mg
📊 Market median: 17.4mg (161 products)
Median 17.4mg This product: 608mg
188 mg
📊 Market median: 500.0mg (193 products) 📚 7 studies — no high-quality reviews
This product: 188mg

Label Claims — Verification

Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

🧪 Formulation Notes

Ultra anabolic muscle protein synthesis activator

Maximize muscle protein synthesis Accelerate muscle growth Stimulate peak amino acid levels

Additional Information

Nothing compares

Product Details

DSLD Entry Date 2021-02-25
Product Type Other Combinations
Form Capsule
Brand 1st Phorm
DSLD ID 242704
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →